Effect of zanamivir on duration and resolution of influenza symptoms
References (18)
Influenza: Quantifying morbidity and mortality
Am J Med.
(1987)- et al.
Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: A randomized, double-blind, placebo-controlled European study
J. Infect.
(2000) - et al.
Efficacy of influenza vaccine in nursing homes: Reduction in illnesses and complications during an influenza A (H3N2) epidemic
JAMA
(1985) Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
MMWR
(2000)- et al.
Implication of viral resistance to amantadine in control of influenza A
Clin Infect Dis.
(1992) - et al.
Emergence and apparent transmission of rimantadine-resistant influenza A virus in families
N Engl J Med.
(1989) Monitoring of viral susceptibility: New challenges with the development of influenza NA inhibitors
Rev Med Virol.
(2000)A novel approach to antiviral therapy for influenza
J Antimicrob Chemother.
(1999)- et al.
Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies
Antimicrob Agents Chemother.
(2000)
Cited by (32)
Influenza Viruses
2018, Principles and Practice of Pediatric Infectious DiseasesAntigen-specific H1N1 influenza antibody responses in acute respiratory tract infections and their relation to influenza infection and disease course
2014, Journal of Clinical VirologyCitation Excerpt :A score for severity of symptoms (SOS) was calculated for each patient as they presented to the ED. The previously validated instrument asked patients to rate, on a scale from 0 (none) to 3 (severe), the severity of seven symptoms: cough, nasal obstruction, sore throat, fatigue, headache, myalgia, and feverishness [20,21]. During January through March of 2009, we used the rapid point-of-care Enzyme-Linked Immunosorbent Assay (ELISA) to screen patients presenting to the ED who were suspected of having an acute infection with influenza.
C-reactive protein as predictor of bacterial infection among patients with an influenza-like illness
2013, American Journal of Emergency MedicineCitation Excerpt :In order to compare the baseline characteristics of the group, a severity of symptom score was calculated for each patient as the presented to the ED. This previously validated severity of symptom (SOS) score was calculated by asking participants to record the severity of 7 symptoms: cough, nasal obstruction, sore throat, fatigue, headache, myalgia, and feverishness [15,16]. The patients rated the severity of each symptom on a scale from 0 being none to 3 being severe.
Influenza Viruses
2012, Principles and Practice of Pediatric Infectious Diseases, Fourth EditionComputational analysis and modeling the effectiveness of 'Zanamivir' targeting neuraminidase protein in pandemic H1N1 strains
2011, Infection, Genetics and EvolutionCitation Excerpt :It is found to be effective against wide range of influenza A and B viruses both in vitro and in laboratory animals by preventing release of progeny virions budding out from cell surface (Ferraris et al., 2005; Colman, 1999; Barnett et al., 2000). Administration by inhalation results in direct delivery to the respiratory tract, the principal site of viral replication (Monto et al., 2000). Mutation in a nearby residue of the drug binding site plays a vital role in the binding affinity of the drug with the corresponding protein.
Design and performance testing of quantitative real time PCR assays for influenza A and B viral load measurement
2004, Journal of Clinical Virology